NCT06391034View on ClinicalTrials.gov

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

October 31, 2032

Conditions
Prostate Cancer
Interventions
DRUG

hyperpolarized pyruvate +/-urea (13C/15N)

Given IV

RADIATION

Non-investigational Stereotactic body radiotherapy (SBRT)

Stereotactic body radiotherapy given outside of this study

PROCEDURE

Radiotherapy (RT)

Radiation therapy given outside of this study

PROCEDURE

Multi-parametric magnetic resonance imaging (mpMRI)

Imaging scan

BIOLOGICAL

Non-interventional hormone therapy

Therapy given outside of this study as part of standard of care

PROCEDURE

Prostate Biopsy

Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Robert Bok, MD, PhD

OTHER